The purpose of this study is to evaluate the effect of zinc supplementation on insulin secretion by genotype of SLC30A8.

NCT00981448

Conditions

1. Diabetes

Interventions

1. Dietary Supplement: Zinc acetate

MeSH:Diabetes Mellitus

HPO:Diabetes mellitus

Inclusion Criteria: - aged 21-70 years - Amish decent - genotyping of rs13266634 of SLC30A8 gene - previously consented to contact for future studies and future use of DNA Exclusion Criteria: - Subject is a first-degree relative of another subject with the same SLC30A8 genotype - diabetes mellitus (by history, treatment or random BG>200 mg;dl) - gastrointestinal disease causing nausea, vomiting, or diarrhea including inflammatory bowel disease by history.

- rheumatoid arthritis by history - albumin < 3.5 g/dL - hemochromatosis by history - hematocrit <34% - liver disease by history - alanine aminotransferase or aspartate aminotransferase greater than 2.5 times normal - renal failure by history - estimated glomerular filtration rate < 60 mL/min by MDRD equation - use of thiazide diuretic and unwilling to discontinue if deemed safe in the opinion of the treating physician and study physician for 1 week prior to protocol initiation - use of systemic corticosteroid and unwilling to discontinue if deemed safe in the opinion of the treating physician and study physician for 1 week prior to protocol initiation - use of highly-active antiretroviral medications - use of antipsychotic medications - use of quinolone antibiotics - use of tetracycline antibiotic and unwilling to discontinue if deemed safe in the opinion of the treating physician and study physician for 1 week prior to protocol initiation - use of chelation therapy in the past month - unwilling to withdraw from supplements for 1 week prior to the study and throughout study - abnormal thyroid stimulating hormone (TSH) level - serious disease precluding participation - reported pregnancy or positive urine hCG test - cancer diagnosis in past 2 years - breastfeeding - use of denture adhesive Inclusion Criteria: - aged 21-70 years - Amish decent - genotyping of rs13266634 of SLC30A8 gene - previously consented to contact for future studies and future use of DNA Exclusion Criteria: - Subject is a first-degree relative of another subject with the same SLC30A8 genotype - diabetes mellitus (by history, treatment or random BG>200 mg;dl) - gastrointestinal disease causing nausea, vomiting, or diarrhea including inflammatory bowel disease by history.

Study whether SLC30A8 rs13266634 polymorphism is associated with type 2 diabetes mellitus (T2DM) susceptibility in Egyptian patients and study effect of Zn supplementation on glycemic control in patients with type 2 diabetes

NCT03112382

Conditions

1. Diabetes Mellitus, Type II

Interventions

1. Drug: zinc supplement plus vitamin A and E
2. Drug: vitamin A and E

MeSH:Diabe Diabetes Mellitus Diabetes Mellitus, Type 2

HPO:Diabetes mellitus Type II diabetes mellitus

Effect of SLC30A8 rs13266634 Genetic Polymorphism on Zinc Supplementation and Glycemic Control in Egyptian Patients With Type 2 Diabetes Mellitus Study whether SLC30A8 rs13266634 polymorphism is associated with type 2 diabetes mellitus (T2DM) susceptibility in Egyptian patients and study effect of Zn supplementation on glycemic control in patients with type 2 diabetes SLC30A8 rs13266634 polymorphism.